HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

treatment regimen without compromising efficacy.

"This phase II study evaluated DVd as an alternative to the VAD regimen. With DVd, DOXIL is administered as a one hour infusion (compared to a 96 hour infusion with VAD, which also requires indwelling venous access), and vincristine as an IV push every 28 days. The results from this study are encouraging and further study of the DVd regimen in multiple myeloma is warranted," said Mohamad A. Hussein, M.D., Director of the Multiple Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center, the lead investigator of the study.

About Multiple Myeloma and DOXIL
There are more than 14,600 new cases of myeloma in the U.S. each year, representing 20 percent of blood cancers and 1 percent of all types of cancer. Multiple myeloma is a cancer of plasma cells. Plasma cells are normally present in the bone marrow and are responsible for antibody production in response to infection and other immune triggering events. In myeloma, a defective plasma cell (myeloma cell) gives rise to the much larger number of myeloma cells which build up in the bone marrow. This process disrupts the normal immune system as well as displacing the normal bone marrow cells. 1

Indication
DOXIL is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. DOXIL also is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy.

These indications are based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, suc
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical study reports findings combination therapy with DOXIL

(Date:8/28/2014)... WASHINGTON, Aug. 28, 2014A new method for measuring and ... help doctors and researchers better understand how drug abuse ... surgery and tissue engineering, and lead to better treatment ... by a team of researchers from Stony Brook University ... of Health, was published today in The Optical Society,s ...
(Date:8/28/2014)... of new roads will be built worldwide by 2050. ... wildernesses, where they bring an influx of destructive loggers, ... study has created a ,global roadmap, for prioritising road ... competing demands of development and environmental protection. , The ... that natural importance of ecosystems and a ,road-benefits, layer ...
(Date:8/28/2014)... homes could pose a significant health risk to people with ... Journal of Allergy and Clinical Immunology . , By critically ... the research has found that the presence of several types ... as well as increasing the likelihood of developing the condition. ... the University of Exeter Medical School and is the first ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Indoor mold poses health risk to asthma sufferers 2
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces ... available in its catalogue: Global ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About ... that are readily decomposed by the action ... non-degradable packaging in terms of raw materials, ...
(Date:8/27/2014)... 27, 2014 The Global and China ... on the current state of the Trifluoroacetic Acid industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5
Cached News: